PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control TerminatedThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cheaper MS drug could match pricey standard in major trial
Disease control OngoingThis phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a cancer drug slow MS progression? new trial halted midway
Disease control TerminatedThis phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a stronger dose of ocrevus slow MS disability better?
Disease control OngoingThis Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New MS drug tolebrutinib tested for Long-Term safety in 2,500 patients
Disease control OngoingThis study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Stem cells from amniotic fluid tested for progressive MS – but trial pulled
Disease control TerminatedThis study aimed to test whether stem cells from amniotic fluid, injected into the spinal fluid, could safely help people with progressive multiple sclerosis (MS). The trial was designed for adults aged 18–60 with primary or secondary progressive MS. However, the study was withdr…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New MS drug candidate made available to patients before approval
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is designed for people who have no other treatment options. The goal is to provide the drug while researchers continue to study its safety and effectivenes…
Matched conditions: PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC